Navigation Links
GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
Date:12/1/2011

FARMINGTON, Conn., Dec. 1, 2011 /PRNewswire-iReach/ -- Global Information, Inc. presents "Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018"  by GlobalData.

(Photo:  http://photos.prnewswire.com/prnh/20111201/CG15993)

Polycystic ovarian syndrome (PCOS) is a common chronic disorder of the endocrine system in women. It mostly affects women of reproductive age (12-45 years old) and is thought to be one of the main causes of female subfertility. It is characterized by a heterogeneous appearance of anovulation, hyperandrogenemia, or secondary metabolic problems such as obesity, insulin resistance and so on.

Other names for this syndrome are polycystic ovary disease (PCOD), functional ovarian hyperandrogenism, Stein-Leventhal syndrome, ovarian hyperthecosis and sclerocystic ovary syndrome

Static growth in the PCOS Therapeutics Market in the Forecast Period

The global PCOS market was valued at $656m in 2010; GlobalData estimates the PCOS market to reach $804m by 2018 growing at a CAGR of 2.6% in the forecast period.

The rising prevalent population of co-morbid conditions such as diabetes, obesity and dyslipidemia are the key driver for the static growth in PCOS therapeutics market. The market does not have an approved drug. Treatment options include generic and off-label drugs which have lower efficacy profiles, which mean that both physician and patient satisfaction are low.

The etiology and pathology of PCOS is not clearly understood. Therefore it is difficult to identify the cause of the disease and develop a drug against it, which means that the current therapies rely on treating the symptoms rather than the diseas
'/>"/>

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
2. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
3. A New Target in Polycystic Kidney Disease
4. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
5. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
6. OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
9. BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers
10. EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
11. For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SAN JOSE, California , 2 marzo 2015 ... che ha aperto la strada alla fusione con ... dell,articolazione sacroiliaca (SI) con iFuse Implant System ® ... iFuse sono stati eseguiti nel mondo intero utilizzando ... tecnica chirurgica iFuse viene sempre più adottata guadagnando ...
(Date:3/2/2015)... March 2, 2015 Shire plc (LSE: ... company has submitted a New Drug Application (NDA) with the ... lifitegrast for the treatment of signs and symptoms of dry ... be the first treatment indicated to address both the signs ... which affects millions of people," said Philip J. Vickers ...
(Date:3/2/2015)... N.J. and BETHESDA, Md. ... development-stage immunotherapy company focused on treating and preventing autoimmune ... 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... exclusive license agreement, Celimmune has the rights to develop, ... excluding Japan . Concurrently, Amgen has ...
Breaking Medicine Technology:SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 2SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 3SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 4Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 2Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 3Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 4Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3
... SAN DIEGO, Jan. 9, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... for 2012, with a strong focus on driving the global ... presentation at the 30th Annual J.P. Morgan Healthcare Conference in ... Bradbury highlighted steps the company is taking to prepare for ...
... 9, 2012   Remedi SeniorCare , one of the ... skilled nursing, assisted living and retirement communities, announced that ... only long-term care pharmacy to have its electronic order ... Pharmacy for electronic prescribing.  "This is ...
Cached Medicine Technology:Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 2Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 3Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 4Remedi SeniorCare® Wins Ohio State Board of Pharmacy's First and Only Approval for Electronic Prescribing in State of Ohio 2
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, released ... The white paper by WEDI’s ICD-10 Testing Subworkgroup provides ... by focusing on primary considerations and steps for external ... 1, 2015 implementation date. Download the white paper ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 Dinner preparation and ... to the success of DinnerDork , a ... and delicious for thousands of busy customers. The ... by expanding to offer a total of 6 ... seasonally appropriate classic recipes and comfort foods; Paleo ...
(Date:3/2/2015)... Regulatory Compliance Associates® Inc. (RCA), ... and technical consulting, announces Mr. Seyed Khorashahi has ... , Before joining RCA, Mr. Khorashahi had over ... all aspects of developing safety-critical medical devices. ... Regulatory Compliance Associates Inc., Baxter Healthcare, and Beckman ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
Breaking Medicine News(10 mins):Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... Study finds twice the incidence of ,food insecurity, , , TUESDAY, ... smokers are more likely to be underfed and undernourished, a ... members of smoking households, but children feel the impact the ... at New York University School of Medicine. , "We know ...
... 4 AlphaDetail, Inc. is growing.,As a leader ... to the Global Life Sciences Industry, the company ... senior staff members to its Professional,Services Group., ... based in,Alphadetail,s San Mateo, California headquarters office. Gloria ...
... Misonix, Inc.,(Nasdaq: MSON ), today announced that ... supplier of after market products, services,and test equipment ... study in Sweden at the country,s annual clinical ... was presented by the School,for Technology and Health, ...
... organs and other internal structures of the human body. ... that can predict the sound transmission of improved designs ... processing large quantities of data and can be run ... University Medical Centre and Oldelft Ultrasound are now using ...
... 2008) In the first-ever study of its kind, a ... Research Institute at Harbor-UCLA Medical Center (LA BioMed) report ... Hispanics took longer to respond to medication for depression ... English-speaking Hispanics. , Using data from the nation,s largest ...
... by nearly 100%, operating loss reduced by 44%, ... ), a leading provider of quantitative imaging for clinical,trials, ... 2008 were,over $1.8 million, a 33% increase over prior ... 30, 2008 were approximately $5.2,million compared to nearly $4.2 ...
Cached Medicine News:Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:AlphaDetail, Inc. Continues Bi-coastal Expansion 2Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 2Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 3Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 4Health News:Response rates to antidepressants differ among English- and Spanish-speaking Hispanics 2Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 2Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 3Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 4Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 5Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 6
... Endovenous Laser System is designed to help ... in the leg. Endovenous laser therapy is ... the treatment of varicose veins., In endovenous ... inserted into the varicosed vein, generally through ...
... high-power, long-pulse Nd:YAG technology provides practitioners with the ... lesions and perform permanent hair reduction on all ... size feature allows the practitioner to instantly switch ... spot size with a simple twist of the ...
...
...
Medicine Products: